Emerging Threat: Carfentanil in Counterfeit Tablets, Powders
A forensic deep-dive into how a veterinary elephant sedative — 10,000 times more potent than morphine — is quietly replacing fentanyl inside counterfeit "M30" tablets and illicit powders seized at the U.S. Southwest Border.
When law enforcement seizes small blue pills stamped "M30," everyone assumes they contain fentanyl. That assumption may now be fatally wrong. Forensic scientists at the Center for Forensic Science Research and Education (CFSRE) have confirmed a chilling new trend: carfentanil — not fentanyl — as the sole opioid in counterfeit tablets, and as a deadly co-adulterant in illicit powders. This is the most dangerous shift in the illicit drug supply in nearly a decade.
What Is Carfentanil? A Forensic Profile
Carfentanil is a synthetic opioid first synthesised in the 1970s as a large-animal veterinary tranquiliser — designed specifically to immobilise elephants and other megafauna. It was never approved for human use. It is a Schedule II controlled substance in the United States and is regulated under international drug control conventions.
The compound binds to mu-opioid receptors with extraordinary affinity — roughly 100 times greater than fentanyl and approximately 10,000 times that of morphine. A lethal dose for a human is estimated at the nanogram level, compared to the 2 mg fentanyl dose the DEA identifies as potentially fatal.
Carfentanil first emerged in the U.S. illicit drug supply in the mid-2010s, adulterating heroin supplies in the Midwest and causing mass overdose events. It largely disappeared after 2017 — until now.
A single outlier tablet in CFSRE's May 2025 analysis contained 0.15 mg of carfentanil. Accounting for its 100× potency relative to fentanyl, this is equivalent to 15 mg of fentanyl — more than seven times the DEA's estimated lethal dose for a non-tolerant individual.
The SENTINEL Program: How These Findings Came to Light
The alarming new data comes from the SENTINEL program — a surveillance initiative between the CFSRE, U.S. Customs and Border Protection (CBP), and the Colombo Plan Drug Advisory Program (DAP). Under SENTINEL, seized tablets and powders suspected of containing fentanyl from the U.S. Southwest Border are submitted to CFSRE for rigorous forensic analysis.
The multi-tiered laboratory workflow includes:
- 1Microscopic Imaging — High-resolution documentation of tablet morphology, colour, markings, and diameter (~6.55 mm for counterfeit M30s).
- 2GC/MS (Gas Chromatography–Mass Spectrometry) — Initial qualitative screening and compound identification.
- 3LC-QTOF-MS (Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry) — High-resolution qualitative identification of unknowns, including trace analogs.
- 4LC-MS/MS (Liquid Chromatography Tandem Mass Spectrometry) — Precise quantitative analysis measuring exact concentrations in mg/tablet or percentage by weight.
This multi-modal approach is what allowed forensic scientists to detect carfentanil even at trace levels and confirm its presence as the sole opioid — not merely a contaminant — in the tablet cases.
The Tablet Cases: Carfentanil Alone, No Fentanyl
Starting in May 2025, CFSRE received two separate batches of counterfeit "M30" oxycodone tablets seized from the Southwest Border. These pills are blue, monogrammed with "M" inside a square on one face and "30" on the other — the classic appearance that has become synonymous with fentanyl counterfeit tablets.
| Case | Received | Tablets | Avg. Carfentanil/Tablet | Range | Fentanyl? | Other Compounds |
|---|---|---|---|---|---|---|
| Case 1 | May 2025 | 30 (7 tested) | 0.03 mg | 0.01–0.15 mg | ❌ None detected | Acetaminophen, Metamizole |
| Case 2 | August 2025 | 30 (7 tested) | 0.02 mg | 0.017–0.024 mg | ❌ None detected | Acetaminophen, Metamizole |
The wide variability in Case 1 (0.01 to 0.15 mg per tablet) reflects the well-documented "hot spot" problem in forensic toxicology — uneven distribution of active pharmaceutical ingredient in illicitly pressed tablets due to poor manufacturing quality control. This makes every single pill in a batch a different risk level, even from the same batch.
The Powder Cases: Fentanyl + Carfentanil, Variable Potency
Around the same period, CFSRE received two exhibits of purple-coloured powder — a presentation distinctly different from the blue tablet stereotype. Both powders contained fentanyl as the primary compound, but carfentanil was confirmed as a deadly co-adulterant in both samples.
| Case | Date | Appearance | Fentanyl % | Carfentanil % | Other Adulterants |
|---|---|---|---|---|---|
| Powder Case 1 | June 2025 | Violet-purple | 16.34% | 0.31% | Lidocaine (0.52%), Xylazine (0.39%) |
| Powder Case 2 | September 2025 | Light purple | 1.01% | 0.04% | Lidocaine (0.12%), Xylazine (0.11%), Procaine |
The fentanyl concentration alone varied sixteen-fold between these two samples (1.01% vs 16.34%). Additional compounds identified by LC-QTOF-MS included synthesis precursors, intermediates, and byproducts — chemical fingerprints that give forensic chemists clues about manufacturing methods and the probable source laboratory.
The presence of xylazine ("tranq" — a veterinary sedative) in both powder cases is an additional compounding concern. Xylazine is not an opioid and does not respond to naloxone, complicating emergency treatment. The combined presence of carfentanil, fentanyl, and xylazine creates a potentially unsurvivable overdose scenario.
The Broader Crisis: DEA Data & National Trends
DEA Laboratory Identifications Surge
According to DEA records, carfentanil was identified in U.S. drug seizures 1,400 times in 2025 — a staggering rise from 145 identifications in 2023 and just 54 in 2022. This nearly 26-fold increase in three years signals a dramatic shift in illicit drug manufacturing and trafficking supply chains.
Major Enforcement Seizures
In September 2025, the DEA Seattle Field Division, working with ATF and local police, seized 50,208 counterfeit M30 pills at a gas station in Centralia, Washington. Lab analysis confirmed the pills contained no fentanyl — only carfentanil and acetaminophen. The following month, the DEA Los Angeles Field Division seized 628,000 pills containing carfentanil — the largest single confiscation in U.S. history.
Death Toll Climbing
CDC data (MMWR, December 2024) confirmed that overdose deaths with carfentanil detected increased approximately sevenfold — from 29 deaths during January–June 2023 to 238 during January–June 2024 — across 37 states. The National Drug Early Warning System (NDEWS) documented over 4,515 hospital ER encounters involving non-fatal carfentanil overdoses between January 2023 and January 2026, with over 85% occurring in Northeastern states.
"Anyone who takes a pill that is not prescribed to them by their doctor is playing a game of Russian roulette with their life."
Supply Chain: Where Is It Coming From?
Law enforcement and forensic investigators believe the carfentanil resurgence is driven by multiple converging factors. U.S. Customs and Border Protection reported that fentanyl seizures plunged to approximately 12,000 pounds in 2025 — less than half of 2023 levels. Trafficking organisations may be pivoting to carfentanil precisely because its extreme potency means vastly more doses can be moved in much smaller, easily concealed packages.
Traffickers in Mexico are suspected to be experimenting with domestic carfentanil production, while other supply routes may involve China-based vendors advertising on international online forums. The extreme manufacturing hazards — even trace dermal or respiratory exposure can kill unprotected workers — make this a uniquely dangerous production environment that limits the number of producers.
Forensic Laboratory Implications: What Labs Must Do
The CFSRE and Colombo Plan have issued a direct call to action for forensic laboratories worldwide. The imperatives from their April 2026 public health alert:
- 1Comprehensive opioid testing: All opioids present must be tested for and reported — not just the predominant one. Carfentanil at low concentrations is easily overlooked if labs only quantify the primary compound.
- 2High-resolution instrumentation: LC-QTOF-MS or equivalent is essential for detecting trace carfentanil in complex matrices. GC/MS screening alone may miss it.
- 3Quantitative reporting: Qualitative identification is insufficient. Precise mg/tablet or weight-percentage quantification is required to properly assess lethality risk.
- 4Monitor for "Orphines" and new analogs: CFSRE flagged newly emergent compounds called "Orphines" as an additional concern requiring updated comprehensive screening panels.
- 5Rapid alert dissemination: Forensic findings must be rapidly communicated to public health officials, emergency responders, and harm-reduction services.
Naloxone (Narcan) can reverse carfentanil overdose, but multiple high-dose administrations may be required — significantly more than for standard fentanyl reversals. Where xylazine is co-present (as in the powder cases), naloxone will not address the xylazine component. Wound care and cardiovascular support must be managed separately.
Harm Reduction: The False Security of Fentanyl Test Strips
One of the most alarming public health dimensions of this finding is the critical failure mode it creates in harm-reduction infrastructure. Fentanyl test strips have been distributed widely as a life-saving tool — and they are, for fentanyl. But standard immunoassay fentanyl test strips may not reliably detect carfentanil at the concentrations found in these tablets (0.02–0.03 mg per tablet). A user testing a blue M30 pill could receive a negative result and believe it is "safe" — while holding a dose with 7× the lethal fentanyl equivalent.
This underscores the urgent need for harm-reduction services to transition to multi-drug testing strips or drug-checking services with carfentanil-specific reagents or point-of-care immunoassay validated for carfentanil detection.
A Forensic Expert's Takeaway
For students and professionals in forensic science, this case study is a masterclass in why comprehensive, technology-forward forensic analysis matters. The assumption that a blue M30 pill contains fentanyl — baked into public discourse, test strip design, and some laboratory protocols — is now demonstrably and dangerously wrong.
Carfentanil's reemergence demands:
‣ Investment in LC-QTOF-MS and LC-MS/MS instrumentation
‣ Cross-disciplinary communication between forensic labs, medical examiners & public health
‣ Real-time intelligence sharing between border agencies and laboratory networks
‣ Public health messaging that goes beyond fentanyl to the full synthetic opioid spectrum
The illicit drug supply is not static. As forensic scientists, our surveillance capacity must be equally dynamic. Carfentanil's return is not a surprise to those who study the synthetic opioid market — but the speed and scale of its reentry, and specifically its appearance as the sole opioid in mass-produced counterfeit tablets, represents a new and urgent threat demanding the full capabilities of modern forensic toxicology.
"Forensic laboratories must maintain consistent testing and reporting of all opioids present in seized materials, even when large quantities of less potent opioids are present. Substances such as carfentanil and the newly emergent Orphines highlight the importance of this comprehensive approach."
📄 Sources & References
forensicmag.com — Full Article
cfsre.org — Original PDF Report
dea.gov — Press Release
cdc.gov — MMWR Full Report | PubMed Central
cnn.com — Full Article
abcnews.com — AP Wire Story
psychologytoday.com — Full Article
rainierrehab.org — Full Article
